What type of study is this?

This is a Cross-Sectional Study study.

What question did this study set out to answer?

This research evaluates the clinical utility of MALDI-TOF MS in detecting M protein and minimal residual disease in multiple myeloma patients.

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

This research evaluates the clinical utility of MALDI-TOF MS in detecting M protein and minimal residual disease in multiple myeloma patients.
Cross-sectional study involving 225 multiple myeloma patients
Comparison of MALDI-TOF MS with serum immunofixation (sIFE) and NGF for screening and monitoring
Assessment of sensitivity and specificity for M protein detection at various thresholds
MALDI-TOF MS sensitivity was 89.1% and specificity 54.7% compared to sIFE
The concordance rate between MALDI-TOF MS and sIFE was 69.2% in patients without extramedullary infiltration
MALDI-TOF MS effectively detected Daratumumab in 91.5% of samples during treatment

No takes yet. Share an insight, caveat, or question.

Cross-sectional study finds MALDI-TOF MS detects minimal residual disease in multiple myeloma, indicating potential diagnostic improvements.

Wu et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Cross-sectional study finds MALDI-TOF MS detects minimal residual disease in multiple myeloma, indicating potential diagnostic improvements.